secwatch / observer

8-K filed May 27, 2026, 6:37 AM ET ticker APGE CIK 0001974640

other material confidence high sentiment positive materiality 0.85

Apogee reports positive Phase 2 Part B data for zumilokibart; mid-dose 65.9% EASI-75 vs 23.4% placebo

Apogee Therapeutics, Inc.

Primary endpoint met: 65.9% mid-dose EASI-75 (p<0.001 vs placebo 23.4%) at 16 weeks.
Key secondary endpoints: IGA 0/1 46.0%, EASI-90 47.4%, I-NRS≥4 50.5% (all p<0.001).
Safety consistent with class; conjunctivitis rate for mid-dose 10.6% vs 15.1% low and 20.7% high.
Plans to initiate Phase 3 ADventure trials in 2H 2026; also Phase 2b asthma and Phase 2a EoE trials.
Blackstone Life Sciences strategic financing collaboration announced to fund through commercialization.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-066572
form_type: 8-K
ticker: APGE
cik: 0001974640
company_name: Apogee Therapeutics, Inc.
filed_at: 2026-05-27T10:37:49+00:00
discovered_at: 2026-05-27T10:40:00.300545+00:00
generated_at: 2026-05-27T10:40:38.486994+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-066572
json_url: https://secwatch.observer/filing/0001104659-26-066572.json
markdown_url: https://secwatch.observer/filing/0001104659-26-066572.md
text_url: https://secwatch.observer/filing/0001104659-26-066572.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1974640/000110465926066572/0001104659-26-066572-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1974640/000110465926066572/tm2615568d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001104659-26-066572

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.